Immunosis

About

Immunosis develops Prim-Dx, a diagnostic test for primary immunodeficiency, pursuing regulatory registration in the United States followed by approvals in Australia, Europe, and selected Asian countries.

Mission

Immunosis Pty Ltd is a privately held company developing Prim-Dx, a diagnostic test for primary immunodeficiency (PID). The company has attracted investment from BioScience Managers and, together with scientific and clinical collaborators, received funding from the Victorian Medical Research Acceleration Fund – Round 4. Immunosis aims first to register Prim-Dx in the United States and then to seek regulatory approval in Australia, Europe and selected Asian countries. The company is actively seeking additional investors who are passionate about improving the lives of patients with rare genetic diseases. The articles emphasize the significant health and commercial potential of a successful PID diagnostic: Jeffrey Modell Foundation data cited show hospital days falling from 19.8 to 3.1 and physician/ER visits falling from 70.8 to 11.7 after diagnosis. The Jeffrey Modell Foundation is also cited as estimating that severe, repeated infections impact as many as 1 in 500 people, and that each diagnosed patient yields an annual US healthcare savings of $78,202.

Quick Facts